Cell Line

BDCA-2 is a novel type II C-type lectin, which shows 50.7% sequence identity at the amino acid level to its putative murine ortholog, the murine dendritic cell–associated C-type lectin 2. In addition to its antigen capturing function, BDCA-2 can mediate potent inhibition of induction of IFN-α/β expression in PDCs. Production of IFN-α/β in response to several different types of viruses, bacteria, CpG-DNA, dsRNA, and SLE serum is by far the most prominent feature of PDCs.

BDCA-2 is a novel type II C-type lectin, which shows 50.7% sequence identity at the amino acid level to its putative murine ortholog, the murine dendritic cell–associated C-type lectin 2. In addition to its antigen capturing function, BDCA-2 can mediate potent inhibition of induction of IFN-α/β expression in PDCs. Production of IFN-α/β in response to several different types of viruses, bacteria, CpG-DNA, dsRNA, and SLE serum is by far the most prominent feature of PDCs.

BDCA-2 is a novel type II C-type lectin, which shows 50.7% sequence identity at the amino acid level to its putative murine ortholog, the murine dendritic cell–associated C-type lectin 2. In addition to its antigen capturing function, BDCA-2 can mediate potent inhibition of induction of IFN-α/β expression in PDCs. Production of IFN-α/β in response to several different types of viruses, bacteria, CpG-DNA, dsRNA, and SLE serum is by far the most prominent feature of PDCs.

Recombinant CHO-K1 cells stably express low affinity immunoglobulin gamma Fc region receptor III-A (FcγRIIIa / CD16A 158V) complex on the cell surface, including 1 alpha chain and 2 gamma chains. The surface expression of CD16A is validated by FACS analysis. This stable cell line product is designed for measuring the binding affinity and stability of the Fc region of antibodies, Fc fusion proteins, or antibody based biologics that bind with CD16A 158V. GenScript also offers a stable cell line expressing the CD16A of 158F allotype (Cat. No. M00598) for FcγRIIIa polymorphism study.

Recombinant CHO-K1 cells stably overexpress human immunoglobulin gamma Fc region receptor II-a (FcγRIIa / CD32A 131His). The surface expression of CD32A 131His is validated by FACS analysis. This stable cell line product is designed for measuring binding affinity and stability of Fc region of antibodies and Fc fusion proteins, or antibody based biologics binding with CD32A 131His. GenScript also offers CD32A 131Arg stable cell line (Cat. No. M00887) for FcγRIIa polymorphism study.

Recombinant CHO-K1 cells stably overexpress low affinity immunoglobulin gamma Fc region receptor II-b (FcγRIIb / CD32B 232Thr). The surface expression of CD32B 232Thr is validated by FACS analysis. This stable cell line product is designed for measuring binding affinity and stability of Fc region of antibodies, Fc fusion proteins, or antibody based biologics that bind with CD32B 232Ile. GenScript also offers CD32B 232Ile overexpression stable cell line (Cat. No. M00587) for FcγRIIb polymorphism study.

Recombinant CHO-K1 cells stably overexpress Homo sapiens cell-type natural killer cells Fc gamma receptor IIc1 (FcγRIIc / CD32C) on the cell surface. The surface expression of FcγRIIc is validated by FACS analysis. This stable cell line is recommended for evaluating the binding affinity between FcγRIIc and Fc region of antibodies, Fc fusion proteins, or antibody-based biologics.

Recombinant CHO-K1 cells stably overexpress human Fc fragment of IgG receptor IIIb (FcγRIIIb / CD16B NA1). The surface expression of CD16B NA1 is validated by FACS analysis. This stable cell line product is designed for measuring binding affinity and stability of Fc region of antibodies, Fc fusion proteins, or antibody based biologics that bind with CD16B during biologics research and development.

Recombinant CHO-K1 cells stably overexpress human FcRn and B2M subunits. The B2M subunits enable stable expression of FcRn in cells. Association of FcRn alpha-chain with beta (2) m is also important for IgG binding. The surface expression of FcRn is validated by FACS analysis. This cell can be used in binding assay or as an immunogen.